US 12,258,382 B2
Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
Andrea Mahr, Tuebingen (DE); Toni Weinschenk, Tuebingen (DE); Colette Song, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Tuebingen (DE); and Harpreet Singh, Tuebingen (DE)
Assigned to Immatics Biotechnologies GmbH, Tübungen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Nov. 18, 2021, as Appl. No. 17/529,322.
Application 17/529,322 is a continuation of application No. 17/314,688, filed on May 7, 2021, granted, now 11,939,366.
Application 17/314,688 is a continuation of application No. 17/068,980, filed on Oct. 13, 2020, abandoned.
Application 17/068,980 is a continuation of application No. 16/887,994, filed on May 29, 2020, granted, now 10,829,537, issued on Nov. 10, 2020.
Application 16/887,994 is a continuation of application No. 16/778,915, filed on Jan. 31, 2020, granted, now 10,703,795, issued on Jul. 7, 2020.
Application 16/778,915 is a continuation of application No. 16/582,046, filed on Sep. 25, 2019, granted, now 10,626,162, issued on Apr. 21, 2020.
Application 16/582,046 is a continuation of application No. 16/413,192, filed on May 15, 2019, granted, now 10,487,132, issued on Nov. 26, 2019.
Application 16/413,192 is a continuation of application No. 16/281,155, filed on Feb. 21, 2019, granted, now 10,364,282, issued on Jul. 30, 2019.
Application 16/281,155 is a continuation of application No. 16/137,489, filed on Sep. 20, 2018, granted, now 10,273,282, issued on Apr. 30, 2019.
Application 16/137,489 is a continuation of application No. 15/965,305, filed on Apr. 27, 2018, granted, now 10,294,288, issued on May 21, 2019.
Application 15/965,305 is a continuation of application No. 15/202,388, filed on Jul. 5, 2016, granted, now 10,011,645, issued on Jul. 3, 2018.
Claims priority of provisional application 62/188,870, filed on Jul. 6, 2015.
Claims priority of application No. 1511792 (GB), filed on Jul. 6, 2015.
Prior Publication US 2022/0135646 A1, May 5, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/00 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C07K 14/635 (2006.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/70539 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/001152 (2018.08); A61K 39/4611 (2023.05); A61K 39/4644 (2023.05); C07K 14/4748 (2013.01); C07K 14/635 (2013.01); C07K 14/7051 (2013.01); C07K 16/2833 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57484 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); C07K 2319/70 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01)] 20 Claims
 
1. A peptide consisting of the amino acid sequence ALLDGGSEAYWRV (SEQ ID NO: 8) in the form of a pharmaceutically acceptable salt.